The largest community of pharma leaders

The Power of Habit – Creating Positive Feedback Loops in Healthcare

Did you know that almost half of all decisions are based on habits? However, that does not mean that we cannot change our habits (and thereby make better decisions)!

Focusing on habits in healthcare, there are a lot of questions around this topic. For example, how are habits formed? What factors influence the sustainability of habits? Is there a way to help modify HCP habits in a positive way?

In our next webinar, The Power of Habit – Creating Positive Feedback Loops in Healthcare (September 3rd, 2019 | 10am EST, 3pm CET), Natalie Yeadon, Co-owner and Managing Director of Impetus Digital, will answer these questions and many more.In this 30-minute webinar, you will learn:

  • How to leverage prompts to trigger positive HCP behaviours
  • Different ways to make HCP behaviour changes achievable
  • The principles behind HCP behaviour motivation
  • How to leverage virtual platforms to inspire habits

Spots are limited; register today so that you don’t miss out! http://bit.ly/2zkQG1EIf you can’t join us live, don’t worry. We’ll send a link to a recording to all those who sign up.

About Natalie Yendon: Natalie worked in the pharmaceutical industry for over 18 years in a variety of sales, marketing, and early brand commercialization management roles. Currently, she is the Co-owner and Managing Director of Impetus Digital where she dedicates her time to helping life science companies create sustained and authentic relationships with their key customers through Impetus’ cutting-edge online collaboration platform, the Impetus InSite Platform®.

Recent Articles

Reven Pharmaceuticals Reports on the Importance of Micronutrients and Vitamins for COVID-19 in a Prestigious Medical Journal

GOLDEN, Colo.--(BUSINESS WIRE)--Reven Holdings, Inc. (“Reven”), a privately held clinical stage biotechnology and pharmaceutical company dedicated to the discovery and development of novel treatment...

Anthony Welters Joins Gilead Sciences’ Board of Directors

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Anthony Welters has been appointed to the company’s Board of Directors. Mr. Welters retired...

AVIA Names Linda Finkel as CEO

CHICAGO--(BUSINESS WIRE)--AVIA, the nation’s leading digital transformation partner for healthcare organizations, announced that its board of directors has appointed AVIA President Linda Finkel to...

Goldfinch Bio Presents Clinical Data from Phase 1 Trial Supporting Advancement of GFB-887 as a Precision Medicine for Patients with Kidney Diseases

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced...

U.S. Food and Drug Administration Approves Gilead’s Antiviral Veklury® (remdesivir) for Treatment of COVID-19

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the antiviral drug Veklury®...